title: The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
abstract: BACKGROUND
  Binding of allergens with IgE to the IgE receptors on mast cells and basophils results in the release of inflammatory mediators as sulfidoleukotrienes (SLTs), triggering allergic cascades that result in allergic symptoms, such as asthma and rhinitis.
  
  
  OBJECTIVE
  We sought to investigate whether anti-IgE (Oma-lizumab), a humanized monoclonal anti-IgE antibody, in addition to specific immunotherapy (SIT) affects the leukotriene pathway.
  
  
  METHODS
  Ninety-two children (age range, 6-17 years) with sensitization to birch and grass pollens and with seasonal allergic rhinitis were included in a phase III, placebo- controlled, multicenter clinical study. All subjects were randomized to one of 4 treatment groups. Two groups subcutaneously received birch SIT and 2 groups received grass SIT for at least 14 weeks before the start of the birch pollen season. After 12 weeks of SIT titration, placebo or anti-IgE was added for 24 weeks. The primary clinical efficacy variable was symptom load (ie, the sum of daily symptom severity score and rescue medication score during pollen season). Blood samples taken at baseline and at the end of study treatment after the grass pollen season were used for separation of leukocytes in this substudy. After in vitro stimulation of the blood cells with grass and birch pollen allergens, SLT release (LTC4, LTD4, and LTE4) was quantified by using the ELISA technique.
  
  
  RESULTS
  Before the study treatment, SLT release to birch and grass pollen exposure did not differ significantly among the 4 groups. Under treatment with anti-IgE + SIT-grass (n = 23), a lower symptom load occurred during the pollen season compared to placebo + SIT-grass (n = 24, P =.012). The same applied to both groups receiving birch SIT (n = 23 and n = 22, respectively; P =.03). At the end of treatment, the combination of anti-IgE plus grass SIT, as well as anti-IgE plus birch SIT, resulted in significantly lower SLT release after stimulation with the corresponding allergen (416 ng/L [5th-95th percentile, 1-1168] and 207 ng/L [1-860 ng/L], respectively) compared with placebo plus SIT (2490 ng/L [384-6587 ng/L], P =.001; 2489 ng/L [1-5670 ng/L], P =.001). In addition, treatment with anti-IgE was also followed by significantly lower SLT releases to the allergens unrelated to SIT (grass SIT: 300 ng/L [1-2432 ng/L] in response to birch allergen; birch SIT: 1478 ng/L [1-4593 ng/L] in response to grass pollen) in comparison with placebo (grass SIT: 1850 ng/L [1-5499 ng/L], P =.001; birch SIT: 2792 ng/L [154-5839 ng/L], P =.04].
  
  
  CONCLUSIONS
  Anti-IgE therapy reduces leukotriene release of peripheral leukocytes stimulated with allergen in children with allergic rhinitis undergoing allergen immunotherapy independent of the type of SIT allergen used.
authors.affiliation: University Children's Hospital, Freiburg, Germany.
authors.forename: Matthias Volkmar
authors.initials: MV
authors.lastname: Kopp
authors.forename: Jens
authors.initials: J
authors.lastname: Brauburger
authors.forename: Frank
authors.initials: F
authors.lastname: Riedinger
authors.forename: Dorothee
authors.initials: D
authors.lastname: Beischer
authors.forename: Gabriele
authors.initials: G
authors.lastname: Ihorst
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Kamin
authors.forename: Stefan
authors.initials: S
authors.lastname: Zielen
authors.lastname: Bez
authors.forename: Frank
authors.initials: F
authors.lastname: Friedrichs
authors.forename: Andrea
authors.initials: A
authors.lastname: Von Berg
authors.forename: Kerstin
authors.initials: K
authors.lastname: Gerhold
authors.forename: Eckard
authors.initials: E
authors.lastname: Hamelmann
authors.lastname: Hultsch
authors.forename: Joachim
authors.initials: J
authors.lastname: Kuehr
mesh_terms: D000293:Adolescent; D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D029662:Betula / Q000276:immunology; D002648:Child; D003131:Combined Modality Therapy; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D015289:Leukotrienes / Q000096:biosynthesis*; D008297:Male; D000069444:Omalizumab; D006109:Poaceae / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015289:Leukotrienes; C026408:anti-IgE antibodies; D000069444:Omalizumab